Denosumab (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Denosumab" in English language version.

refsWebsite

Global rank English rank

24web.archive.org

1^st place

17nih.gov

4^th place

15europa.eu

68^th place

117^th place

8doi.org

2^nd place

4hpfb-dgpsa.ca

low place

4fda.gov

447^th place

338^th place

2samsungbioepis.com

low place

1tga.gov.au

3,984^th place

2,622^nd place

1landesbioscience.com

low place

1amgen.com

low place

1drugs.com

399^th place

333^rd place

1semanticscholar.org

11^th place

8^th place

1todaysgeriatricmedicine.com

low place

1psu.edu

207^th place

136^th place

1urotoday.com

low place

1nytimes.com

7^th place

1medpagetoday.com

9,274^th place

5,856^th place

1biosciencetechnology.com

low place

1genengnews.com

low place

6,625^th place

1cancer.gov

1,684^th place

1,350^th place

1globenewswire.com

2,614^th place

1,549^th place

1yahoo.com

38^th place

40^th place

amgen.com

"Prolia (denosumab)". Products. Amgen. Archived from the original on 29 September 2015. Retrieved 6 May 2012.

biosciencetechnology.com

Matthew Perrone (2 June 2010). "FDA clears Amgen's bone-strengthening drug Prolia". BioScience Technology. Archived from the original on 27 August 2010. Retrieved 2 June 2010.

cancer.gov

"FDA Approval for Denosumab". Archived from the original on 6 April 2015. Retrieved 31 August 2013.

doi.org

Pageau SC (2009). "Denosumab". mAbs. 1 (3): 210–5. doi:10.4161/mabs.1.3.8592. PMC 2726593. PMID 20065634. Archived from the original on 8 March 2012. Retrieved 27 March 2011.
McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, et al. (February 2006). "Denosumab in postmenopausal women with low bone mineral density". The New England Journal of Medicine. 354 (8): 821–31. doi:10.1056/NEJMoa044459. PMID 16495394.
Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, et al. (November 2012). "Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials". European Journal of Cancer. 48 (16): 3082–92. doi:10.1016/j.ejca.2012.08.002. PMID 22975218.
Josse R, Khan A, Ngui D, Shapiro M (March 2013). "Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis". Current Medical Research and Opinion. 29 (3): 205–16. doi:10.1185/03007995.2013.763779. PMID 23297819. S2CID 206967103.
Nayak S, Greenspan SL (March 2017). "Osteoporosis Treatment Efficacy for Men: A Systematic Review and Meta-Analysis". Journal of the American Geriatrics Society. 65 (3): 490–495. doi:10.1111/jgs.14668. PMC 5358515. PMID 28304090.
Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. (August 2009). "Denosumab for prevention of fractures in postmenopausal women with osteoporosis". The New England Journal of Medicine. 361 (8): 756–65. CiteSeerX 10.1.1.472.3489. doi:10.1056/NEJMoa0809493. PMID 19671655.
Khosla S (August 2009). "Increasing options for the treatment of osteoporosis". The New England Journal of Medicine. 361 (8): 818–20. doi:10.1056/NEJMe0905480. PMC 3901579. PMID 19671654.
Boyce AM (August 2017). "Denosumab: an Emerging Therapy in Pediatric Bone Disorders". Current Osteoporosis Reports. 15 (4): 283–292. doi:10.1007/s11914-017-0380-1. PMC 5554707. PMID 28643220.

drugs.com

"Denosumab". The American Society of Health-System Pharmacists. Archived from the original on 30 April 2021. Retrieved 16 March 2015.

europa.eu

ema.europa.eu

"Jubbonti EPAR". European Medicines Agency. 21 March 2024. Archived from the original on 23 March 2024. Retrieved 23 March 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Obodence EPAR". European Medicines Agency (EMA). 14 November 2024. Retrieved 16 November 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Osenvelt EPAR". European Medicines Agency (EMA). 12 December 2024. Retrieved 16 December 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Wyost EPAR". European Medicines Agency. 21 March 2024. Archived from the original on 23 March 2024. Retrieved 23 March 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Xbryk EPAR". European Medicines Agency (EMA). 14 November 2024. Retrieved 16 November 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Prolia EPAR". European Medicines Agency. 26 May 2010. Archived from the original on 16 September 2021. Retrieved 6 March 2024.
"Xgeva EPAR". European Medicines Agency. 13 July 2011. Archived from the original on 21 September 2023. Retrieved 6 March 2024.
"European Public Assessment Report (EPAR) for Prolia" (PDF). European Medicines Agency (EMA). 16 October 2014. Archived from the original (PDF) on 4 March 2016. Retrieved 13 April 2015.
"Stoboclo EPAR". European Medicines Agency (EMA). 12 December 2024. Retrieved 16 December 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 March 2024". European Medicines Agency (Press release). 22 March 2024. Retrieved 13 June 2024.
"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 November 2024". European Medicines Agency (EMA) (Press release). 15 November 2024. Retrieved 16 November 2024.

ec.europa.eu

"Obodence PI". Union Register of medicinal products. 13 February 2025. Retrieved 16 February 2025.
"Xbryk PI". Union Register of medicinal products. 13 February 2025. Retrieved 16 February 2025.
"Prolia PI". Union Register of medicinal products. 28 May 2010. Archived from the original on 21 January 2022. Retrieved 6 March 2024.
"Xgeva PI". Union Register of medicinal products. 15 July 2011. Archived from the original on 19 August 2018. Retrieved 6 March 2024.

fda.gov

accessdata.fda.gov

https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761362s000lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761392Orig1s000lbl.pdf
"Jubbonti BLA #761362" (PDF). U.S. Food and Drug Administration (FDA). Archived (PDF) from the original on 6 March 2024. Retrieved 5 March 2024.

fda.gov

"Prolia (denosumab): Drug Safety Communication - FDA Adds Boxed Warning for Increased Risk of Severe Hypocalcemia in Patients with Advanced Chronic Kidney Disease Archived 6 April 2024 at the Wayback Machine". U.S. Food and Drug Administration, 19 January 2024.

genengnews.com

"Amgen's Denosumab Cleared by FDA for Second Indication". 19 November 2010. Archived from the original on 7 April 2018. Retrieved 27 November 2010.

globenewswire.com

"Sandoz receives FDA approval for first and only denosumab biosimilars" (Press release). Sandoz. 5 March 2024. Archived from the original on 6 March 2024. Retrieved 6 March 2024 – via GlobeNewswire.

hpfb-dgpsa.ca

dhpp.hpfb-dgpsa.ca

"Regulatory Decision Summary for Jubbonti". Drug and Health Products Portal. 16 February 2024. Archived from the original on 1 April 2024. Retrieved 1 April 2024.
"Regulatory Decision Summary for Wyost". Drug and Health Products Portal. 1 March 2024. Archived from the original on 1 April 2024. Retrieved 1 April 2024.
"Summary Basis of Decision for Wyost". Drug and Health Products Portal. Retrieved 13 November 2024.
"Summary Basis of Decision for Jubbonti". Drug and Health Products Portal. Retrieved 13 November 2024.

landesbioscience.com

Pageau SC (2009). "Denosumab". mAbs. 1 (3): 210–5. doi:10.4161/mabs.1.3.8592. PMC 2726593. PMID 20065634. Archived from the original on 8 March 2012. Retrieved 27 March 2011.

medpagetoday.com

"FDA Approves Denosumab for Osteoporosis". 2 June 2010. Archived from the original on 13 June 2018. Retrieved 27 November 2010.

nih.gov

pubmed.ncbi.nlm.nih.gov

Pageau SC (2009). "Denosumab". mAbs. 1 (3): 210–5. doi:10.4161/mabs.1.3.8592. PMC 2726593. PMID 20065634. Archived from the original on 8 March 2012. Retrieved 27 March 2011.
McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, et al. (February 2006). "Denosumab in postmenopausal women with low bone mineral density". The New England Journal of Medicine. 354 (8): 821–31. doi:10.1056/NEJMoa044459. PMID 16495394.
Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, et al. (November 2012). "Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials". European Journal of Cancer. 48 (16): 3082–92. doi:10.1016/j.ejca.2012.08.002. PMID 22975218.
Zhou Z, Chen C, Zhang J, Ji X, Liu L, Zhang G, et al. (2014). "Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis". International Journal of Clinical and Experimental Pathology. 7 (5): 2113–22. PMC 4069896. PMID 24966919.
Josse R, Khan A, Ngui D, Shapiro M (March 2013). "Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis". Current Medical Research and Opinion. 29 (3): 205–16. doi:10.1185/03007995.2013.763779. PMID 23297819. S2CID 206967103.
Nayak S, Greenspan SL (March 2017). "Osteoporosis Treatment Efficacy for Men: A Systematic Review and Meta-Analysis". Journal of the American Geriatrics Society. 65 (3): 490–495. doi:10.1111/jgs.14668. PMC 5358515. PMID 28304090.
Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. (August 2009). "Denosumab for prevention of fractures in postmenopausal women with osteoporosis". The New England Journal of Medicine. 361 (8): 756–65. CiteSeerX 10.1.1.472.3489. doi:10.1056/NEJMoa0809493. PMID 19671655.
Khosla S (August 2009). "Increasing options for the treatment of osteoporosis". The New England Journal of Medicine. 361 (8): 818–20. doi:10.1056/NEJMe0905480. PMC 3901579. PMID 19671654.
Boyce AM (August 2017). "Denosumab: an Emerging Therapy in Pediatric Bone Disorders". Current Osteoporosis Reports. 15 (4): 283–292. doi:10.1007/s11914-017-0380-1. PMC 5554707. PMID 28643220.

ncbi.nlm.nih.gov

Pageau SC (2009). "Denosumab". mAbs. 1 (3): 210–5. doi:10.4161/mabs.1.3.8592. PMC 2726593. PMID 20065634. Archived from the original on 8 March 2012. Retrieved 27 March 2011.
Zhou Z, Chen C, Zhang J, Ji X, Liu L, Zhang G, et al. (2014). "Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis". International Journal of Clinical and Experimental Pathology. 7 (5): 2113–22. PMC 4069896. PMID 24966919.
Nayak S, Greenspan SL (March 2017). "Osteoporosis Treatment Efficacy for Men: A Systematic Review and Meta-Analysis". Journal of the American Geriatrics Society. 65 (3): 490–495. doi:10.1111/jgs.14668. PMC 5358515. PMID 28304090.
Khosla S (August 2009). "Increasing options for the treatment of osteoporosis". The New England Journal of Medicine. 361 (8): 818–20. doi:10.1056/NEJMe0905480. PMC 3901579. PMID 19671654.
EntrezGene 8600 TNFSF11 tumor necrosis factor (ligand) superfamily, member 11; Homo sapiens
also known as RANKL. This protein was shown to be a dentritic cell survival factor and is involved in the regulation of T cell-dependent immune response.
Boyce AM (August 2017). "Denosumab: an Emerging Therapy in Pediatric Bone Disorders". Current Osteoporosis Reports. 15 (4): 283–292. doi:10.1007/s11914-017-0380-1. PMC 5554707. PMID 28643220.

dailymed.nlm.nih.gov

"Prolia- denosumab injection". DailyMed. 24 January 2024. Archived from the original on 7 June 2023. Retrieved 6 March 2024.
"Xgeva- denosumab injection". DailyMed. 9 June 2020. Archived from the original on 13 April 2023. Retrieved 6 March 2024.

nytimes.com

Pollack A (19 October 2009). "F.D.A. Says No to an Amgen Bone Drug". The New York Times. Archived from the original on 27 January 2018. Retrieved 24 February 2017.

psu.edu

citeseerx.ist.psu.edu

Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. (August 2009). "Denosumab for prevention of fractures in postmenopausal women with osteoporosis". The New England Journal of Medicine. 361 (8): 756–65. CiteSeerX 10.1.1.472.3489. doi:10.1056/NEJMoa0809493. PMID 19671655.

samsungbioepis.com

"FDA Approves Samsung Bioepis Ospomyv, Xbryk (denosumab-dssb), a Biosimilar to Prolia and Xgeva". Samsung Bioepis (Press release). 16 February 2025. Retrieved 16 February 2025.
"Samsung Bioepis Gains European Commission (EC) Approval for Denosumab Biosimilar (Obodence, Xbryk)". Samsung Bioepis (Press release). 16 February 2025. Retrieved 16 February 2025.

semanticscholar.org

api.semanticscholar.org

Josse R, Khan A, Ngui D, Shapiro M (March 2013). "Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis". Current Medical Research and Opinion. 29 (3): 205–16. doi:10.1185/03007995.2013.763779. PMID 23297819. S2CID 206967103.

tga.gov.au

"Jubbonti (Sandoz Pty Ltd)". Therapeutic Goods Administration (TGA). 13 September 2024. Retrieved 15 September 2024.

todaysgeriatricmedicine.com

"Injectable Prolia — Osteoporosis Update". Archived from the original on 9 March 2021. Retrieved 23 March 2016.

urotoday.com

"Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting". PRNewswire/FirstCall. 13 August 2009. Archived from the original on 3 November 2013. Retrieved 17 September 2009.

web.archive.org

"Regulatory Decision Summary for Jubbonti". Drug and Health Products Portal. 16 February 2024. Archived from the original on 1 April 2024. Retrieved 1 April 2024.
"Jubbonti EPAR". European Medicines Agency. 21 March 2024. Archived from the original on 23 March 2024. Retrieved 23 March 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Regulatory Decision Summary for Wyost". Drug and Health Products Portal. 1 March 2024. Archived from the original on 1 April 2024. Retrieved 1 April 2024.
"Wyost EPAR". European Medicines Agency. 21 March 2024. Archived from the original on 23 March 2024. Retrieved 23 March 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Prolia- denosumab injection". DailyMed. 24 January 2024. Archived from the original on 7 June 2023. Retrieved 6 March 2024.
"Xgeva- denosumab injection". DailyMed. 9 June 2020. Archived from the original on 13 April 2023. Retrieved 6 March 2024.
"Prolia EPAR". European Medicines Agency. 26 May 2010. Archived from the original on 16 September 2021. Retrieved 6 March 2024.
"Xgeva EPAR". European Medicines Agency. 13 July 2011. Archived from the original on 21 September 2023. Retrieved 6 March 2024.
Pageau SC (2009). "Denosumab". mAbs. 1 (3): 210–5. doi:10.4161/mabs.1.3.8592. PMC 2726593. PMID 20065634. Archived from the original on 8 March 2012. Retrieved 27 March 2011.
"European Public Assessment Report (EPAR) for Prolia" (PDF). European Medicines Agency (EMA). 16 October 2014. Archived from the original (PDF) on 4 March 2016. Retrieved 13 April 2015.
"Prolia (denosumab)". Products. Amgen. Archived from the original on 29 September 2015. Retrieved 6 May 2012.
"Denosumab". The American Society of Health-System Pharmacists. Archived from the original on 30 April 2021. Retrieved 16 March 2015.
"Injectable Prolia — Osteoporosis Update". Archived from the original on 9 March 2021. Retrieved 23 March 2016.
"Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting". PRNewswire/FirstCall. 13 August 2009. Archived from the original on 3 November 2013. Retrieved 17 September 2009.
Pollack A (19 October 2009). "F.D.A. Says No to an Amgen Bone Drug". The New York Times. Archived from the original on 27 January 2018. Retrieved 24 February 2017.
"FDA Approves Denosumab for Osteoporosis". 2 June 2010. Archived from the original on 13 June 2018. Retrieved 27 November 2010.
Matthew Perrone (2 June 2010). "FDA clears Amgen's bone-strengthening drug Prolia". BioScience Technology. Archived from the original on 27 August 2010. Retrieved 2 June 2010.
"Amgen's Denosumab Cleared by FDA for Second Indication". 19 November 2010. Archived from the original on 7 April 2018. Retrieved 27 November 2010.
"FDA Approval for Denosumab". Archived from the original on 6 April 2015. Retrieved 31 August 2013.
"Prolia (denosumab): Drug Safety Communication - FDA Adds Boxed Warning for Increased Risk of Severe Hypocalcemia in Patients with Advanced Chronic Kidney Disease Archived 6 April 2024 at the Wayback Machine". U.S. Food and Drug Administration, 19 January 2024.
"Jubbonti BLA #761362" (PDF). U.S. Food and Drug Administration (FDA). Archived (PDF) from the original on 6 March 2024. Retrieved 5 March 2024.
"Sandoz receives FDA approval for first and only denosumab biosimilars" (Press release). Sandoz. 5 March 2024. Archived from the original on 6 March 2024. Retrieved 6 March 2024 – via GlobeNewswire.
"Prolia PI". Union Register of medicinal products. 28 May 2010. Archived from the original on 21 January 2022. Retrieved 6 March 2024.
"Xgeva PI". Union Register of medicinal products. 15 July 2011. Archived from the original on 19 August 2018. Retrieved 6 March 2024.

yahoo.com

finance.yahoo.com

"Sandoz receives European Commission approval for Wyost and Jubbonti, the first and only biosimilars of denosumab in Europe". Yahoo Finance. 22 May 2024. Retrieved 23 May 2024.